Tinzaparin

Summary

Tinzaparin (CHEMBL6068592) is a phase-3 clinical-stage oligosaccharide targeting SERPINC1; indicated across 3 conditions including colorectal adenocarcinoma and plasma cell myeloma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligosaccharide
• Targets: 1 (SERPINC1)
• Indications: 3 conditions
• Clinical trials: 29

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068592
Name	Tinzaparin
Type	Oligosaccharide
Max phase	3

Also known as: Tinzaparin, TINZAPARIN

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
SERPINC1	serpin family C member 1	Activation		0%	P01008

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): SERPINC1.

Top Reactome pathways

12 total, by targets touching each:

Pathway	Targets	Genes
Hemostasis	1	SERPINC1
R-HSA-140837	1	SERPINC1
R-HSA-140875	1	SERPINC1
R-HSA-140877	1	SERPINC1
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	1	SERPINC1
Metabolism of proteins	1	SERPINC1
Post-translational protein modification	1	SERPINC1
Post-translational protein phosphorylation	1	SERPINC1
Fibrin formation	1	SERPINC1
Initiation of coagulation cascade	1	SERPINC1
Regulation of clotting cascade	1	SERPINC1
Amplification and propagation of coagulation cascade	1	SERPINC1

Dominant GO biological processes

GO term	Targets
blood coagulation	1
regulation of blood coagulation	1
hemostasis	1

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
colorectal adenocarcinoma	3	MONDO:0005008	EFO:0000365
plasma cell myeloma	2	MONDO:0009693	EFO:0001378

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 29.

Phase distribution

Phase	Trials
PHASE4	11
Not specified	10
PHASE3	5
PHASE2	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05245877	PHASE4	RECRUITING	Pre- Vs. Postoperative Thromboprophylaxis in Pancreatic Surgery
NCT05255003	PHASE4	RECRUITING	STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis
NCT07361679	PHASE4	RECRUITING	LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention
NCT00407641	PHASE4	WITHDRAWN	Effects of Tinzaparin on Cardio-vascular Outcomes and on Blood Lipids in Diabetic Patients on Chronic Hemodialysis
NCT00689520	PHASE4	COMPLETED	Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis
NCT00711308	PHASE4	COMPLETED	Tinzaparin in the Treatment of the Acute Pulmonary Embolism
NCT00851864	PHASE4	COMPLETED	Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing
NCT01390051	PHASE4	COMPLETED	Can Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?
NCT01930396	PHASE4	COMPLETED	Use of Tinzaparin for Anticoagulation in Hemodialysis
NCT03614741	PHASE4	UNKNOWN	Efficacy, Safety and Pharmacokinetics of Tinzaparin During Slow Low Efficient Daily Dialysis in Intensive Care Patients
NCT04794569	PHASE4	TERMINATED	Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome
NCT00225108	PHASE2/PHASE3	COMPLETED	The STOP CLOT Pilot Study: Study of Low Molecular Weight Heparin in High Risk Cesarean Section
NCT00475098	PHASE3	COMPLETED	Effect of Low Molecular Weight Heparin: Tinzaparin in Lung Tumours (TILT)
NCT00628576	PHASE3	COMPLETED	Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities
NCT01455831	PHASE3	COMPLETED	Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer
NCT03240120	PHASE3	UNKNOWN	A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
NCT05625932	PHASE3	COMPLETED	TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer
NCT02260414	PHASE2	COMPLETED	Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer
NCT04808882	PHASE2	COMPLETED	ANTIcoagulation in Severe COVID-19 Patients
NCT04741464	Not specified	ACTIVE_NOT_RECRUITING	Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis
NCT07559643	Not specified	NOT_YET_RECRUITING	The OAT Trail: The Obesity Anti-Coagulation Thromboprophylaxis Trial.
NCT00135863	Not specified	TERMINATED	MesoHep II: Intraperitoneal Low Molecular Weight Heparin in Peritoneal Dialysis
NCT00186745	Not specified	TERMINATED	Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure
NCT00967148	Not specified	COMPLETED	Thromboprophylaxis for Patients Undergoing Surgical Resection for Colon Cancer
NCT01321788	Not specified	UNKNOWN	Venous Thromboembolism Prophylaxis Post Cesarean Section
NCT02719418	Not specified	COMPLETED	Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses
NCT03099031	Not specified	COMPLETED	Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)
NCT04730856	Not specified	COMPLETED	Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID)
NCT05036824	Not specified	UNKNOWN	Intensive Dose Tinzaparin in Hospitalized COVID-19 Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

2 molecules share ≥1 primary target. Top 2 by shared-target count:

Molecule	Source	Status	Shared targets
IDRAPARINUX	ChEMBL	Phase 3	SERPINC1
fondaparinux	PubChem	Approved	SERPINC1